AFP and neoplasm: Apart from the common cancer types, sintilimab was involved in suppressing tumor progression on a KRAS positive patient with hepatoid adenocarcinoma (HAC), a sort of rare tumor secreting AFP with morphological similarities to HCC, and eventually achieved a 52-month OS [32].